Life sciences businesses offered accelerator support at Alderley Park
Life sciences businesses are being invited to join a six month accelerator programme at Alderley Park.
Ten businesses will then form the first cohort of Bruntwood SciTech’s new Life Science Accelerator who will gain access to support valued at approximately £60,000.
As well lab space provided by Bruntwood SciTech – a joint venture between Bruntwood, Legal & General and Greater Manchester Pension Fund – successful applicants will receive personalised support aimed at accelerating their idea from lab through to commercialisation.
The project is being funded by the UK Government through the UK Shared Prosperity Fund which has committed £2.6 billion to local investment by March 2025.
Partners in the accelerator include Triple Chasm, ThermoFisher Scientific, Marks & Clerk, Pharmalytical Services, Mercia Ventures and Praetura Group.
Participating biotech entrepreneurs will get laboratory access, supplemented by access to pay-per-use scientific equipment via the Open Access Lab, which equates to over £20,000 worth of laboratory support and kit access.
Triple Chasm, a leading expert in sustainable commercialisation of science and technology-enabled innovation, will provide tools and programmes underpinned by data from more than 3,000 products being taken to markets globally.
Dr Kath Mackay, Chief Scientific Officer at Bruntwood SciTech, said: “The new Life Science Accelerator programme truly embodies our dedication to supporting early-stage life science companies across the UK by providing them with the necessary resources and guidance to thrive. Our mission is to empower these companies to bring their innovative ideas to fruition, ultimately contributing to the advancement of the life sciences sector and the broader economy.
“Launching this programme at Alderley Park allows participants to tap into the vibrant ecosystem of scientific companies and foster valuable networking opportunities, enriching the community and driving further collaboration.”
The launch of the new Life Science Accelerator follows a strong 2023 for R&D funding at Alderley Park, with figures released earlier in 2024 showing that businesses at the Park had secured nearly £50 million in new R&D-linked funding over the past year.
